Payment overview · 2025
General Payments
$4,704.08
99 reported records · 20 companies
Healthcare provider profile · identity verified
Leon A Cohen, MD
Allopathic & Osteopathic Physicians|Family Medicine · MERRITT ISLAND, FL · NPI 1558329607
Verified facts
What the public records show
CMS Open Payments records show Leon A Cohen, MD received $4,704.08 in general payments during 2025 across 99 reported records.
AstraZeneca Pharmaceuticals LP accounted for 28.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 35 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 450 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 159 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Xarelto by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Entresto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $1,338.39 | 28.4% | 18 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $426.19 | 9.1% | 6 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $424.18 | 9.0% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $412.92 | 8.8% | 21 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $391.43 | 8.3% | 16 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $250.00 | 5.3% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $248.20 | 5.3% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $197.73 | 4.2% | 7 | 2025 |
| Dendreon Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $149.86 | 3.2% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $147.02 | 3.1% | 9 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $125.00 | 2.7% | 1 | 2025 |
| PharmaEssentia USA Corporation | Unresolved — no canonical attribution shown | $125.00 | 2.7% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $124.46 | 2.6% | 1 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $124.46 | 2.6% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $107.54 | 2.3% | 5 | 2025 |
| Cipher Pharmaceuticals US LLC | Unresolved — no canonical attribution shown | $29.99 | 0.6% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $24.01 | 0.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $22.63 | 0.5% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.47 | 0.4% | 1 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $16.60 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $4,704.08 | 99 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CARVYKTI Normalized: carvykti |
Drug | Janssen Biotech, Inc. | $424.18 | 3 | 2025 |
Source payment records
|
|||||
| RYBREVANT Normalized: rybrevant |
Drug | Janssen Biotech, Inc. | $424.18 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $412.92 | 21 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $337.25 | 12 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $318.43 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $274.85 | 7 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $250.00 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $248.20 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $197.73 | 7 | 2025 |
Source payment records
|
|||||
| PROVENGE Normalized: provenge |
Drug | Dendreon Pharmaceuticals LLC | $149.86 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $147.02 | 9 | 2025 |
Source payment records
|
|||||
| BESREMI Normalized: besremi |
Drug | PharmaEssentia USA Corporation | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| CALQUENCE Normalized: calquence |
Drug | AstraZeneca Pharmaceuticals LP | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| DATROWAY Normalized: datroway |
Biological | AstraZeneca Pharmaceuticals LP | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| OPDIVO Normalized: opdivo |
Biological | E.R. Squibb & Sons, L.L.C. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| REBLOZYL Normalized: reblozyl |
Biological | E.R. Squibb & Sons, L.L.C. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| SARCLISA Normalized: sarclisa |
Biological | GENZYME CORPORATION | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| ELAHERE Normalized: elahere |
Drug | ABBVIE INC. | $124.46 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $124.46 | 1 | 2025 |
Source payment records
|
|||||
| LIBTAYO Normalized: libtayo |
Biological | Regeneron Healthcare Solutions, Inc. | $124.46 | 1 | 2025 |
Source payment records
|
|||||
| Nubeqa Normalized: nubeqa |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $124.46 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $107.54 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $90.33 | 10 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $51.73 | 3 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $41.30 | 2 | 2025 |
Source payment records
|
|||||
| Natroba Normalized: natroba |
Drug | Cipher Pharmaceuticals US LLC | $29.99 | 1 | 2025 |
Source payment records
|
|||||
| Spinosad Normalized: spinosad |
Drug | Cipher Pharmaceuticals US LLC | $29.99 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $24.01 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $22.63 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $22.63 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $18.47 | 1 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $16.60 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $12.88 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 450 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 96 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 49 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
450 | 100 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
159 | 43 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
96 | 24 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
104 | 21 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 940 | 96 |
| Allopurinol | Allopurinol | 824 | 201 |
| Atorvastatin Calcium | Atorvastatin Calcium | 747 | 184 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 648 | 81 |
| Gabapentin | Gabapentin | 559 | 111 |
| Metformin Hcl | Metformin Hcl | 534 | 130 |
| Lisinopril | Lisinopril | 529 | 134 |
| Diclofenac Sodium | Diclofenac Sodium | 494 | 126 |
| Amlodipine Besylate | Amlodipine Besylate | 479 | 119 |
| Farxiga | Dapagliflozin Propanediol | 450 | 100 |
| Levothyroxine Sodium | Levothyroxine Sodium | 409 | 93 |
| Metoprolol Succinate | Metoprolol Succinate | 328 | 73 |
| Alendronate Sodium | Alendronate Sodium | 316 | 78 |
| Oxycodone Hcl | Oxycodone Hcl | 272 | 40 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 270 | 54 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 270 | 61 |
| Tamsulosin Hcl | Tamsulosin Hcl | 264 | 63 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 254 | 62 |
| Omeprazole | Omeprazole | 246 | 57 |
| Duloxetine Hcl | Duloxetine Hcl | 230 | 57 |
| Trazodone Hcl | Trazodone Hcl | 230 | 46 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 219 | 57 |
| Furosemide | Furosemide | 203 | 43 |
| Ezetimibe | Ezetimibe | 198 | 47 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 184 | 46 |
| Prednisone | Prednisone | 180 | 104 |
| Simvastatin | Simvastatin | 180 | 46 |
| Tizanidine Hcl | Tizanidine Hcl | 178 | 30 |
| Nortriptyline Hcl | Nortriptyline Hcl | 175 | 36 |
| Losartan Potassium | Losartan Potassium | 172 | 47 |
| Cefdinir | Cefdinir | 161 | 107 |
| Symbicort | Budesonide/Formoterol Fumarate | 159 | 43 |
| Escitalopram Oxalate | Escitalopram Oxalate | 156 | 39 |
| Buspirone Hcl | Buspirone Hcl | 154 | 31 |
| Carvedilol | Carvedilol | 151 | 33 |
| Clonazepam | Clonazepam | 141 | 17 |
| Alprazolam | Alprazolam | 139 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 136 | 31 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 123 | 17 |
| Ibandronate Sodium | Ibandronate Sodium | 123 | 38 |
| Pregabalin | Pregabalin | 120 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 119 | 26 |
| Pantoprazole Sodium | Pantoprazole Sodium | 115 | 30 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 108 | 17 |
| Xarelto | Rivaroxaban | 104 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 101 | 21 |
| Potassium Chloride | Potassium Chloride | 100 | 27 |
| Ibuprofen | Ibuprofen | 97 | 27 |
| Jardiance | Empagliflozin | 96 | 24 |
| Finasteride | Finasteride | 92 | 21 |
| Meloxicam | Meloxicam | 92 | 24 |
| Buprenorphine Hcl | Buprenorphine Hcl | 90 | 11 |
| Morphine Sulfate Er | Morphine Sulfate | 89 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 89 | 49 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 88 | 22 |
| Topiramate | Topiramate | 87 | 18 |
| Famotidine | Famotidine | 86 | 16 |
| Fenofibrate | Fenofibrate Nanocrystallized | 86 | 28 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 86 | 22 |
| Pioglitazone Hcl | Pioglitazone Hcl | 85 | 20 |
| Tramadol Hcl | Tramadol Hcl | 85 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 82 | 19 |
| Montelukast Sodium | Montelukast Sodium | 80 | 15 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 78 | 21 |
| Methadone Hcl | Methadone Hcl | 77 | suppressed |
| Amoxicillin | Amoxicillin | 75 | 35 |
| Azithromycin | Azithromycin | 75 | 58 |
| Fluticasone Propionate | Fluticasone Propionate | 72 | 19 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 71 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 69 | 14 |
| Estradiol | Estradiol | 68 | 14 |
| Promethazine Hcl | Promethazine Hcl | 68 | suppressed |
| Lorazepam | Lorazepam | 67 | 12 |
| Glimepiride | Glimepiride | 66 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 64 | 46 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 64 | suppressed |
| Methotrexate | Methotrexate Sodium | 63 | 14 |
| Mirtazapine | Mirtazapine | 63 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 61 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 59 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 58 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 58 | 37 |
| Bupropion Xl | Bupropion Hcl | 55 | 13 |
| Nystatin | Nystatin | 54 | 21 |
| Methylprednisolone | Methylprednisolone | 53 | 47 |
| Spironolactone | Spironolactone | 52 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 51 | 14 |
| Methimazole | Methimazole | 51 | 12 |
| Propranolol Hcl | Propranolol Hcl | 50 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 49 | 36 |
| Risedronate Sodium | Risedronate Sodium | 49 | 16 |
| Vraylar | Cariprazine Hcl | 49 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 48 | 13 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 48 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 48 | suppressed |
| Eliquis | Apixaban | 47 | suppressed |
| Mupirocin | Mupirocin | 45 | 23 |
| Fluconazole | Fluconazole | 44 | 25 |
| Mometasone Furoate | Mometasone Furoate | 43 | 12 |
| Clonidine | Clonidine | 42 | suppressed |
| Levetiracetam | Levetiracetam | 42 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 42 | 11 |
| Dexlansoprazole Dr | Dexlansoprazole | 41 | 13 |
| Doxepin Hcl | Doxepin Hcl | 41 | suppressed |
| Linzess | Linaclotide | 40 | suppressed |
| Methocarbamol | Methocarbamol | 40 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 40 | 14 |
| Rybelsus | Semaglutide | 40 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 39 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 39 | 12 |
| Ondansetron Odt | Ondansetron | 39 | 14 |
| Varenicline Tartrate | Varenicline Tartrate | 37 | suppressed |
| Entresto | Sacubitril/Valsartan | 36 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 36 | suppressed |
| Metronidazole | Metronidazole | 36 | 33 |
| Ozempic | Semaglutide | 35 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 35 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 34 | 21 |
| Aripiprazole | Aripiprazole | 33 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 33 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 32 | suppressed |
| Myrbetriq | Mirabegron | 28 | suppressed |
| Januvia | Sitagliptin Phosphate | 27 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 26 | suppressed |
| Baclofen | Baclofen | 25 | suppressed |
| Lamotrigine | Lamotrigine | 25 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 25 | 11 |
| Testosterone Cypionate | Testosterone Cypionate | 25 | suppressed |
| Valsartan | Valsartan | 25 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 24 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 24 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 23 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 22 | suppressed |
| Lidocaine | Lidocaine | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | suppressed |
| Olanzapine | Olanzapine | 21 | suppressed |
| Mounjaro | Tirzepatide | 20 | suppressed |
| Phenobarbital | Phenobarbital | 20 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Cephalexin | Cephalexin | 19 | 15 |
| Diazepam | Diazepam | 19 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 19 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 19 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 18 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 16 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Permethrin | Permethrin | 16 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 15 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 15 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Estarylla | Norgestimate-Ethinyl Estradiol | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Pentoxifylline | Pentoxifylline | 13 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 12 | 11 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 11 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 11 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 11 | suppressed |
| Naproxen Sodium | Naproxen Sodium | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $4,704.08 · 99 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, BESREMI, BREZTRI, CALQUENCE, CAPLYTA, CARVYKTI, Cologuard Collection Kit, DATROWAY, ELAHERE, EVENITY, FANAPT, FARXIGA, JARDIANCE, KRYSTEXXA, Kerendia, LEQVIO, LIBTAYO, Leqembi, MAVYRET, NEXLETOL, Natroba, Nubeqa, OPDIVO, OTEZLA, PROVENGE, REBLOZYL, REPATHA, RYBREVANT, SARCLISA, SHINGRIX, SUBLOCADE, Spinosad, UBRELVY, VRAYLAR | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error